

Share Dividend Announcement to Counter Short Selling at Upcoming Conference: NRx Pharmaceuticals (Nasdaq: NRXP)

NRx Pharmaceuticals: Advancements and Initiatives Overview

WILMINGTON, DELAWARE, UNITED STATES , February 20, 2024

/EINPresswire.com/ -- Share Dividend Announcement to Counter Short Selling at Upcoming Conference: NRx Pharmaceuticals ([Nasdaq: NRXP](https://www.nasdaq.com/markets/stocks/stocks-listings/nrxp))

For more information on \$NRXP visit: <https://www.nrxpharma.com/>

Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.


Launch of HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024, Plus Planned Share Dividend to Existing NRXP Shareholders.

Completed Initial Manufacture of IV Infusion and Plans to File FDA New Drug Application for Acute Suicidality Upon Demonstration of 2-ear Shelf Stability.

Received \$5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)



\$NRXP on the NASDAQ



\$NRXP Pipeline

NRXP Eligible for Additional \$324 Million in Development & Sales Milestones, Plus Double-Digit Royalties Upon Approval and Commercialization of NRX-101.

Completing Enrollment for Phase 2b/3 Trial in Suicidal Treatment-Resistant Bipolar Depression in Cooperation with Lotus Pharmaceutical.

Incorporation of HOPE Therapeutics Dedicated to NRX-100 (IV Ketamine) for Suicidal Depression to Patients.



HOPE Therapeutics to be Initially Owned by NXP and current NXP Shareholders via a Planned Tax-Free Dividend.

“

NRx aims to provide state-of-the-art patient & reimbursement support for all of its patients and their clinics, ensuring access to insurance vulnerable populations”

Matthew Duffy, Chief Business Officer

New Drug Application for NRX-100 Expected to be Filed in 1st Half of 2024.

Completion of Enrollment for Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression.

NRx Pharmaceuticals, [Inc. \(Nasdaq: NRXP\)](#) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough

Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

NRXP to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024, Plus Planned Share Dividend to Existing NRXP Shareholders

On February 20th NRXP announced that Dr. Jonathan Javitt, its Chairman and Chief Scientist, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024 in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.

Concurrent with the presentation, NRXP plans to file a proxy statement, subject to board approval, for NRXP shareholders outlining the share structure and seeking a shareholder advisory vote to support the planned share dividend for HOPE Therapeutics. NRXP has received consistent advice from public shareholders that the planned share dividend and royalty coupon be distributed only to shareholders and warrant-holders who execute a covenant not to participate in short sales of the Company's stock.

NRXP Presentation Date: Monday, February 26th, 2024

Time: 2:30 PM ET

Location: The Royale Room, Marriott Marquis, New York City

Registration: <https://bcic.bio.org/registration>

SIMULCAST: BIZTV

Information will be available on the NRx website at <https://ir.nrxpharma.com/events> prior to the conference.



NRx Pharmaceuticals, Inc.
1201 N Orange St., Suite 600
Wilmington, DE 19801
Phone: (484) 254-6134
<https://www.nrxpharma.com/>

Ticker (Exchange)	NRXP-NASDAQ
Recent Price (12/01/2023)	\$0.344
52-week Range	\$0.22 - 1.51
Shares Outstanding	81.9 mm
Market Capitalization	\$28.2 mm
Average 10-day volume	259,600
Insider Ownership >5%	22.3%
Institutional Ownership	5%
EPS (Qtr. ended 09/30/2023)	(\$0.07)
Employees	10

NRx Pharmaceuticals, Inc. (NRXP-NASDAQ)
One-year Stock Chart



DCS-LURASIDONE INTERACTION



COMPANY DESCRIPTION

NRx Pharmaceuticals, Inc. ("NRx" or "the Company") is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders with high unmet medical needs. The Company's foundation product is NRX-101, a patented combination of two FDA-approved drugs—D-cycloserine (DCS)†, an NMDA receptor modulator; and lurasidone, an atypical antipsychotic medication. The Company is assessing the use of NRX-101 in four different indications: suicidal bipolar depression, chronic pain, post-traumatic stress disorder (PTSD), and complicated urinary tract infections (cUTI). Development of NMDA antagonists, such as DCS, as antidepressants has been limited by their potential psychedelic side effects. Furthermore, serotonin-targeted drugs like lurasidone have been limited by their own behavioral side effects, specifically akathisia. Professor Daniel Javitt (NRx Co-founder and Chair of its Scientific Advisory) made the simultaneous discovery that: (1) the psychedelic effects of NMDA antagonist drugs could be reversed by combining them with serotonin-targeted compounds; and (2) NMDA inhibitors, in turn, block the akathisia side effect normally associated with serotonin-targeted drugs. The previously undiscovered synergy between these two drug classes is the subject of 48 issued patents and 43 pending patents owned by or licensed to NRx Pharmaceuticals, and as such, is the medical and scientific basis for the Company's technology platform.

KEY POINTS

- NRx entered into a collaboration with Alkermes Pharmaceuticals for the development and commercialization of NRX-101 in suicidal bipolar depression, with the potential for up to \$330 million in milestones and double-digit royalties.
- NRx is conducting a single Phase 2b/3 trial of NRX-101 for Suicidal Treatment Resistant Bipolar Depression (S-TRBD), with topline clinical data readout expected by Q1 2024, potentially followed by an NDA application shortly thereafter.
- Under the Alkermes agreement, a successful data readout and completion of a Type B meeting with the FDA would trigger a \$10 million payment to NRx, at which point, Alkermes would be responsible for all future development and commercialization costs for this indication.
- NRX-101 is also being evaluated for the treatment of chronic pain as a non-addictive substitute for opioid products. The Company is planning to start a pharmacokinetic study following result readout of a 200-person U.S. Department of Defense-funded trial in treating chronic pain with DCS.
- NRx is assessing plans to create spinoff companies to complete development of NRX-100 (IV ketamine) for acute suicidality and NRX-101 for cUTI, which would potentially provide investors with both capital appreciation and a royalty stream.
- As of September 30, 2023, NRx's cash and cash equivalent position was \$8.9 million.

\$NRXP Research Report



NASDAQ: \$NRXP Hope Science Life

\$5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)

On February 12th NRXP announced the advance of the first \$5 million milestone payment based on the Company's partnership agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW).

NRXP will immediately receive \$5 million of the first milestone, which the Company will use to fund development of NRX-101 through the phase 2 meeting with FDA. As compensation for advancing the milestone, Alvogen and Lotus will receive 4.1 million warrants to purchase NRXP common stock, at a strike price of \$0.40 with a three (3) year term. The second portion of the milestone will be \$4 million and, as before, be triggered by a positive response to the Company's planned end of phase 2 meeting with FDA.

NRXP then remains eligible to receive up to \$320 million in future development and sales milestones, as well as royalty payments escalating to mid-teen percentages on Net Sales, subject to achievement of certain sales volumes. Additionally, Alvogen and Lotus will be responsible for future development and commercialization costs for the NRXP NRX-101 in treatment of bipolar depression with suicidality.

Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report

On February 9th NRXP announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRXP clinical trial in bipolar depression as a material event in its February 7 financial filing. Lotus provides the Asia Pacific component of the NRXP global partnership with Alvogen, Inc.

Lotus reported in the accompanying press release that "Lotus Pharmaceutical's strategic partner, NRXP, has achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for this trial is anticipated in Q2 of this year."

Incorporation of HOPE Therapeutics & Planned Share Dividend/Royalty Coupon

On February 5th NRXP announced the incorporation of HOPE Therapeutics™, a biotechnology company dedicated to bringing NRX-100 (IV Ketamine), which will be re-designated HTX-100, a potentially lifesaving treatment option for patients with Suicidal Depression. The company will initially be owned by NRXP and its current shareholders, who will receive their shares in the form of a dividend with an accompanying royalty coupon tied to future sales of HTX-100, subject to Board approval. This is designed with counsel to not be a taxable event for NRXP shareholders.

HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation. A New Drug Application (NDA) is planned for the first half of 2024, based on more than 1,000 patients treated in well-controlled trials of ketamine in Suicidal Depression together with HOPE's expertise in sterile products formulation.

Importantly, NRXP intends to provide state-of-the-art patient and reimbursement support for all of its patients and their clinics. Access to insurance coverage is critical for providing treatment to this vulnerable population and can only be achieved through development of an FDA-approved product. Additionally, providing an approved, compliant product for patients allows clinics to deliver state-of-the-art care to people suffering from suicidality without fear of legal and regulatory actions.

Completion of Enrollment for Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

On January 22nd NRXP announced completion of enrollment in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. Enrollment of 74 patients exceeded the original target of 70 patients, in order to enhance statistical power of the study. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.

The NRXP Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) enrolled 74 patients with suicidal bipolar depression. This is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.

Top-line results from the NRXP clinical trial are expected later this quarter.

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted

as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
484-254-6134
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/689962391>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.